Description of long-term polypharmacy among schizophrenia outpatients
- 621 Downloads
This large nationwide study describes the prevalence and predictors of long-term antipsychotic polypharmacy among patients with schizophrenia.
A register-based longitudinal study of all people in Finland, who had at least one hospitalization due to schizophrenia during the years 2000–2007 and who were alive on March 1, 2007. Entry to the cohort was defined from the first hospitalization for schizophrenia during the years 2000–2007, and the date of assessment of antipsychotic polypharmacy was March 1, 2007. We studied separately chronic (N = 8,037) and recent onset (N = 8,046) schizophrenia patients. Antipsychotic polypharmacy was defined as overlapping of two or more filled prescriptions of antipsychotics for over 60 days.
In a total 16,083 patients with schizophrenia the prevalence of antipsychotic polypharmacy was 46.2 % (N = 7,436, mean age 47.5 years, male 55 %). The longer the duration of schizophrenia, the more common the antipsychotic polypharmacy. Long index hospitalization and being male significantly associated with antipsychotic polypharmacy among all schizophrenia patients. Especially, in chronic schizophrenia patients, the previous use of benzodiazepine like agents was associated with antipsychotic polypharmacy, but the use of antidepressants associated with less frequent antipsychotic polypharmacy.
Antipsychotic polypharmacy was widely prevalent among patients with schizophrenia and it was associated with long hospitalizations and long duration of illness. Benzodiazepine use was associated with increased risk and antidepressant use with decreased risk of antipsychotic polypharmacy when the effect of other clinical and socioeconomic factors was adjusted. Research is needed of risks and benefits of antipsychotic polypharmacy and augmentation of antipsychotic with other psychoactive drugs.
KeywordsSchizophrenia Antipsychotics Polypharmacy Long-term Outpatient treatment
This study was supported by Janssen-Cilag.
Conflict of interest
The authors declare no conflict of interest.
- 2.Finnish guidelines for treatment of schizophrenia. The Finnish Medical Society Duodecim and the Finnish Psychiatric Association. http://www.terveysportti.fi/xmedia/hoi/hoi35050.pdf. Accessed 16 Nov 2010
- 3.Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, American Psychiatric Association, Steering Committee on Practice Guidelines (2004) Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161(2 Suppl):1–56PubMedGoogle Scholar
- 4.National institute for clinical excellence (NICE) (2009) Clinical Guideline CG82 Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. http://www.nice.org.uk/nicemedia/pdf/CG82NICEGuideline.pdf. Accessed 16 Nov 2010
- 10.Fleschhacker WW, Heikkinen ME, Olie J-P, Landsberg W, Dewaele P, McQuade RD, Loze J-Y, Hennicken D, Kerselaers WS (2010) Effects on adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 13:1115–1125CrossRefGoogle Scholar
- 16.Barbui C, Nose M, Mazzi MA, Thornicroft G, Schene A, Becker T, Bindman J, Leese M, Helm H, Koeter M, Weinmann S, Tansella M (2006) Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int Clin Psychopharmacol 21(6):355–362PubMedCrossRefGoogle Scholar
- 28.Baandrup L, Gasse C, Jensen V, Glenthoj B, Nordentoft M, Lublin H, Fink-Jensen A, Lindhart A, Mortensen P (2010) Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case–control study. J Clin Psychiatry 71(2):103–108PubMedCrossRefGoogle Scholar
- 32.ATC/DDD Index 2006. http://www.whocc.no/atc_ddd_index/. Accessed 24 Aug 2011
- 34.Pickar D, Vinik J, Bartko JJ (2008) Pharmacotherapy of schizophrenia patients: preponderance of off-label drug use. PLoS ONE 3(9):e3150Google Scholar